A sharp rebound in Irish economic activity has provided unexpected momentum to the Eurozone, offering relief as core economies contend with stagnating output.

Boston Scientific shares slid as softer-than-expected sales momentum raised questions about hospital procedural volumes and medtech demand.

Healthcare providers and biopharma firms navigate evolving reimbursement policies, elevated operating costs, and strategic portfolio reviews as investors demand disciplined growth.

Boston Scientific trimmed its annual guidance for a second time, citing fallout from a recent cyber incident alongside persistent operational friction across global healthcare markets.

Bausch + Lomb delivered a profitable quarter and lifted its annual outlook, buoyed by surging international demand across its surgical and vision-care segments.

Healthcare equities navigate margin scrutiny, Medicare Advantage reimbursement adjustments, and strategic biopharma acquisitions as investors reposition for sector resilience.